{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:27:38Z","timestamp":1772753258250,"version":"3.50.1"},"reference-count":110,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1517\/14796694.1.2.221","type":"journal-article","created":{"date-parts":[[2005,6,18]],"date-time":"2005-06-18T14:20:44Z","timestamp":1119104444000},"page":"221-234","source":"Crossref","is-referenced-by-count":46,"title":["Epidermal Growth Factor Receptor Inhibitors in Cancer Treatment"],"prefix":"10.1080","volume":"1","author":[{"given":"Fortunato","family":"Ciardiello","sequence":"first","affiliation":[{"name":"Cattedra di Oncologia Medica,Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale \u2018F Magrassi e A. Lanzara\u2018,Seconda Universit\u00e0 degli Studi di Napoli,\rVia S. Pansini 5,\r80131\rNapoli,\rItaly."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,11,24]]},"reference":[{"key":"e_1_3_1_3_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010093031511"},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"e_1_3_1_3_3_1","first-page":"4","article-title":"The erbB family of receptors and their ligands: multiple targets for therapy.","volume":"2","author":"Salomon DS","year":"2001","unstructured":"Salomon DS , GullickW: The erbB family of receptors and their ligands: multiple targets for therapy.Signal2, 4\u201311 (2001).","journal-title":"Signal"},{"key":"e_1_3_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.13.3159"},{"key":"e_1_3_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/35052073"},{"key":"e_1_3_1_3_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.7.8259"},{"key":"e_1_3_1_3_7_1","first-page":"2884","article-title":"Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.","volume":"5","author":"Akimoto T","year":"1999","unstructured":"Akimoto T , HunterNR, BuchmillerL, MasonK, AngKK, MilasL: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.Clin. Cancer Res.5, 2884\u20132890 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_8_1","first-page":"2405","article-title":"Altered gene expression in drug-resistant human breast cancer cells.","volume":"3","author":"Wosikowski K","year":"1997","unstructured":"Wosikowski K , SchuuruisD, KopsGJPL, SacedaM, BatesSE: Altered gene expression in drug-resistant human breast cancer cells.Clin. Cancer Res.3, 2405\u20132414 (1997).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_9_1","first-page":"747","article-title":"Blockade of receptors for growth factors: an anticancer therapy.","volume":"6","author":"Mendelsohn J","year":"2000","unstructured":"Mendelsohn J : Blockade of receptors for growth factors: an anticancer therapy.Clin. Cancer Res.6, 747\u2013753 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0080003"},{"key":"e_1_3_1_3_11_1","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.","volume":"7","author":"Ciardiello F","year":"2001","unstructured":"Ciardiello F , TortoraG: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.Clin. Cancer Res.7, 2958\u20132970 (2001).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.12.851"},{"key":"e_1_3_1_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.504"},{"key":"e_1_3_1_3_14_1","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.","volume":"1","author":"Goldstein NI","year":"1995","unstructured":"Goldstein NI , PrewettM, ZuklysK, RockwellP, MendelsohnJ: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.Clin. Cancer Res.1, 1311\u20131318 (1995).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_15_1","first-page":"1397","article-title":"Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.","volume":"12","author":"Wu X","year":"1996","unstructured":"Wu X , RubinM, FanZet al.: Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.Oncogene12, 1397\u20131403 (1996).","journal-title":"Oncogene"},{"key":"e_1_3_1_3_16_1","first-page":"3666","article-title":"Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145.","volume":"56","author":"Peng D","year":"1996","unstructured":"Peng D , FanZ, LuY, DeblasioT, ScherH, MendelsohnJ: Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145.Cancer Res.56, 3666\u20133669 (1996).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.23.1770"},{"key":"e_1_3_1_3_18_1","first-page":"909","article-title":"Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.","volume":"5","author":"Ciardiello F","year":"1999","unstructured":"Ciardiello F , BiancoR, DamianoVet al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.Clin. Cancer Res.5, 909\u2013916 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_19_1","first-page":"2957","article-title":"Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.","volume":"4","author":"Prewett M","year":"1998","unstructured":"Prewett M , RothmanM, WaksalH, FeldmanM, BanderNH, HicklinDJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.Clin. Cancer Res.4, 2957\u20132966 (1998).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_20_1","first-page":"257","article-title":"Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.","volume":"5","author":"Perrotte P","year":"1999","unstructured":"Perrotte P , MatsumotoT, InoueKet al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.Clin. Cancer Res.5, 257\u2013265 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_21_1","first-page":"1936","article-title":"Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.","volume":"6","author":"Bruns CJ","year":"2000","unstructured":"Bruns CJ Harbison MT , DavisDWet al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.Clin. Cancer Res.6, 1936\u20131948 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_22_1","first-page":"3739","article-title":"Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.","volume":"6","author":"Ciardiello F","year":"2000","unstructured":"Ciardiello F , BiancoR, DamianoVet al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.Clin. Cancer Res.6, 3739\u20133747 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_23_1","first-page":"4874","article-title":"Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.","volume":"6","author":"Inoue K","year":"2000","unstructured":"Inoue K , SlatonJW, PerrottePet al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.Clin. Cancer Res.6, 4874\u20134884 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1999.14.451"},{"key":"e_1_3_1_3_25_1","first-page":"701","article-title":"In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.","volume":"6","author":"Milas L","year":"2000","unstructured":"Milas L , MasonK, HunterNet al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.Clin. Cancer Res.6, 701\u2013708 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_26_1","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.","volume":"15","author":"Huang SM","year":"1999","unstructured":"Huang SM , BockJM, HarariPM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.Cancer Res.15, 1935\u20131940 (1999).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_27_1","first-page":"4343","article-title":"Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.","volume":"6","author":"Bianco C","year":"2000","unstructured":"Bianco C , BiancoR, TortoraGet al.: Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.Clin. Cancer Res.6, 4343\u20134350 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_28_1","first-page":"2166","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.","volume":"6","author":"Huang S-M","year":"2000","unstructured":"Huang S-M , HarariP: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.Clin. Cancer Res.6, 2166\u20132174 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_29_1","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor.","author":"Ciardiello F","year":"2000","unstructured":"Ciardiello F , CaputoR, BiancoRet al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor.Clin. Cancer Res. 6, 2053\u20132063 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2001.01686.x"},{"key":"e_1_3_1_3_31_1","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor receptor signaling with potential for cancer therapy.","volume":"62","author":"Wakeling A","year":"2002","unstructured":"Wakeling A , GuySP, WoodburnJR, AshtonSE, CurryBJ, BarkerAJ, GibsonKH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor receptor signaling with potential for cancer therapy.Cancer Res.62, 5749\u20135754 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_32_1","first-page":"4885","article-title":"Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.","volume":"6","author":"Sirotnak FM","year":"2000","unstructured":"Sirotnak FM , ZakowskyMF, MillerVA, ScherHI, KrisMG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.Clin. Cancer Res.6, 4885\u20134892 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10239"},{"key":"e_1_3_1_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10230"},{"key":"e_1_3_1_3_35_1","article-title":"ZD1839 (Iressa), an EGFR-TKI, potentiates radiation\/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines.","author":"Raben D","year":"2000","unstructured":"Raben D , HelfrichB, PhistryM, BunnP: ZD1839 (Iressa), an EGFR-TKI, potentiates radiation\/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines.11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands (2000) (Abstract LB4).","journal-title":"11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands"},{"key":"e_1_3_1_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600182"},{"key":"e_1_3_1_3_37_1","first-page":"3250","article-title":"Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (\u2018Iressa\u2018).","volume":"8","author":"Bianco C","year":"2002","unstructured":"Bianco C , TortoraG, BiancoRet al.: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (\u2018Iressa\u2018).Clin. Cancer Res.8, 3250\u20133258 (2002).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_38_1","first-page":"4300","article-title":"Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas.","volume":"62","author":"Huang S","year":"2002","unstructured":"Huang S , LiJ, HarariPM: Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas.Cancer Res.62, 4300\u20134306 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_39_1","first-page":"1459","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.","volume":"7","author":"Ciardiello F","year":"2001","unstructured":"Ciardiello F , CaputoR, BiancoRet al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin. Cancer Res.7, 1459\u20131465 (2001).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf020"},{"key":"e_1_3_1_3_41_1","first-page":"8887","article-title":"Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2\/neu (erbB2)-overexpressing breast cancer cells and in vivo.","volume":"61","author":"Moulder SL","year":"2001","unstructured":"Moulder SL , YakesFM, MuthuswamySK, BiancoR, SimpsonJF, ArteagaCL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2\/neu (erbB2)-overexpressing breast cancer cells and in vivo.Cancer Res.61, 8887\u20138895 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_42_1","first-page":"1274","article-title":"ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR\/HER2 and EGFR\/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.","volume":"9","author":"Anido J","year":"2003","unstructured":"Anido J , MatarP, AlbanellJet al.: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR\/HER2 and EGFR\/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.Clin. Cancer Res.9, 1274\u20131283 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_43_1","first-page":"7184","article-title":"The tyrosine kinase inhibitor ZD1839 (\u201cIressa\u201d) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","volume":"61","author":"Moasser MM","year":"2001","unstructured":"Moasser MM , BassoA, AverbuchSD, RosenN: The tyrosine kinase inhibitor ZD1839 (\u201cIressa\u201d) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.Cancer Res.61, 7184\u20137188 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10194"},{"key":"e_1_3_1_3_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh166"},{"key":"e_1_3_1_3_46_1","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.","volume":"57","author":"Moyer JD","year":"1997","unstructured":"Moyer JD , BarbacciEG, IwataKKet al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.Cancer Res.57, 4838\u20134848 (1997).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_47_1","first-page":"739","article-title":"Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.","volume":"291","author":"Pollack VA","year":"1999","unstructured":"Pollack VA , SavageDM, BakerDAet al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.J. Pharmacol. Exp. Ther.291, 739\u2013748 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_1_3_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.904"},{"key":"e_1_3_1_3_49_1","article-title":"Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR).","volume":"20","author":"Saltz L","year":"2001","unstructured":"Saltz L , RubinM, HochsterHet al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR).Proc. Am. Soc. Clin. Oncol.20 [Abstract 7] (2001).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.182"},{"key":"e_1_3_1_3_51_1","article-title":"Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.","volume":"23","author":"Lenz HJ","year":"2004","unstructured":"Lenz HJ , MayerRJ, GoldPJet al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.Proc. Am. Soc. Clin. Oncol.23 (2004) (Abstract 3510).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_3_1_3_53_1","volume":"23","author":"Rougier P","year":"2004","unstructured":"Rougier P , RasoulJ-L, Van Laethem J-L et\u00a0al.: Cetuximab (Erbitux) combined with FOLFIRI (irinotecan plus infusional 5-FU and folinic acid given every two weeks) in patients with epidermal growth factor receptor-expressing advanced colorectal cancer Proc. Am. Soc. Clin. Oncol.23 [Abstract 3513] (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_54_1","volume":"23","author":"Tabernero JM","year":"2004","unstructured":"Tabernero JM , Van CutsemE, SastreJet al.: An international phase II study of cetuximab in combination with oxaliplatin\/5-fluorouracil (5FU)\/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol.23 [Abstract\u00a03512] (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3234"},{"key":"e_1_3_1_3_56_1","article-title":"Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN).","volume":"23","author":"Bonner JA","year":"2004","unstructured":"Bonner JA , GiraltJ, HarariPMet al.: Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN).Proc. Am. Soc. Clin. Oncol.23 [Abstract\u00a05507] (2004) .","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_57_1","article-title":"Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGFR) C225 in patients (pts) with metastatic\/recurrent head and neck cancer (HNC).","volume":"21","author":"Burtness B","year":"2002","unstructured":"Burtness B , LiY, FloodWet al.: Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGFR) C225 in patients (pts) with metastatic\/recurrent head and neck cancer (HNC).Proc. Am. Soc. Clin. Oncol.21 [Abstract 901] (2002).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_58_1","article-title":"Cetuximab monotherapy is active in patients with platinum-refractory recurrent\/metastatic squamous cell carcinoma of the head and neck (SCCHN).","volume":"23","author":"Trigo J","year":"2004","unstructured":"Trigo J , HittR, KoralewskiPet al.: Cetuximab monotherapy is active in patients with platinum-refractory recurrent\/metastatic squamous cell carcinoma of the head and neck (SCCHN).Proc. Am. Soc. Clin. Oncol.23 [Abstract 5502] (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01137-9"},{"key":"e_1_3_1_3_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.112"},{"key":"e_1_3_1_3_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.038"},{"key":"e_1_3_1_3_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.100"},{"key":"e_1_3_1_3_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg250"},{"key":"e_1_3_1_3_64_1","first-page":"2040","article-title":"Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.","volume":"9","author":"LoRusso P","year":"2003","unstructured":"LoRusso P , HerbstRS, RischinDet al.: Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.Clin. Cancer Res.9, 2040\u20132048 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.001"},{"key":"e_1_3_1_3_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.038"},{"key":"e_1_3_1_3_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.16.2149"},{"key":"e_1_3_1_3_68_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-4-303"},{"key":"e_1_3_1_3_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.039"},{"key":"e_1_3_1_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(03)00079-5"},{"key":"e_1_3_1_3_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601387"},{"key":"e_1_3_1_3_72_1","first-page":"481","article-title":"Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib (\u201cIressa\u201d, ZD1839) in non small cell lung cancer.","volume":"22","author":"Gelibter A","year":"2003","unstructured":"Gelibter A , CeribelliA, MilellaMet al.: Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib (\u201cIressa\u201d, ZD1839) in non small cell lung cancer.J. Exp. Clin. Cancer Res.22, 481\u2013485 (2003).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"e_1_3_1_3_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg153"},{"key":"e_1_3_1_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(03)00189-2"},{"key":"e_1_3_1_3_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_3_1_3_76_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_3_1_3_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405220101"},{"key":"e_1_3_1_3_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe048101"},{"key":"e_1_3_1_3_79_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1101637"},{"key":"e_1_3_1_3_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1905"},{"key":"e_1_3_1_3_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.001"},{"key":"e_1_3_1_3_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.215"},{"key":"e_1_3_1_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13810-X"},{"key":"e_1_3_1_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12190-3"},{"key":"e_1_3_1_3_85_1","first-page":"2","article-title":"Interstitial lung disease in NSCLC.","volume":"4","author":"Soria J-C","year":"2003","unstructured":"Soria J-C , LeChevalier T: Interstitial lung disease in NSCLC.Signal4, 2\u20133 (2003).","journal-title":"Signal"},{"key":"e_1_3_1_3_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3267"},{"key":"e_1_3_1_3_87_1","first-page":"269","volume-title":"Exp. Rev. Anticancer Ther.","author":"Bulgaru AM","year":"2003","unstructured":"Bulgaru AM , ManiS, GoelS, Perez-SolerR: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.Exp. Rev. Anticancer Ther.3, 269\u2013279 (2003)."},{"key":"e_1_3_1_3_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.075"},{"key":"e_1_3_1_3_89_1","article-title":"Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma.","volume":"20","author":"Finkler N","year":"2001","unstructured":"Finkler N , GordonA, CrozierMet al.: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma.Proc. Am. Soc. Clin. Oncol.20 [Abstract] 831 (2001).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.057"},{"key":"e_1_3_1_3_91_1","article-title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) trial.","volume":"23","author":"Shepherd FA","year":"2004","unstructured":"Shepherd FA , PereiraJ, CiuleanuTEet al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) trial.Proc. Am. Soc. Clin. Oncol.23 [Abstract] 7022 (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_92_1","article-title":"Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotehrapy in advanced non-small cell lung cancer (NSCLC).","volume":"23","author":"Gatzemeier U","year":"2004","unstructured":"Gatzemeier U , PluzanskaA, SzczesnaAet al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotehrapy in advanced non-small cell lung cancer (NSCLC).Proc. Am. Soc. Clin. Oncol.23 [Abstract 7010] (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_93_1","article-title":"TRIBUTE \u2013 A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer (NSCLC).","volume":"23","author":"Herbst RS","year":"2004","unstructured":"Herbst RS , PragerD, HermannRet al.: TRIBUTE \u2013 A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer (NSCLC).Proc. Am. Soc. Clin. Oncol.23 [Abstract] 7011 (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_94_1","article-title":"The presence and intensity of the Cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies.","volume":"23","author":"Saltz LB","year":"2003","unstructured":"Saltz LB , KiesMS, AbbruzzeseJL, AzarniaN, NeedleM: The presence and intensity of the Cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies.Proc. Am. Soc. Clin. Oncol.23 [Abstract] 817 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_95_1","article-title":"Rash severty is predictive of increased survival with erlotinib HCl.","volume":"22","author":"Clark GM","year":"2003","unstructured":"Clark GM , Perez-SolerR, SiuL, GordonA, SantabarbaraP: Rash severty is predictive of increased survival with erlotinib HCl.Proc. Am. Soc. Clin. Oncol.22 [Abstract] 786 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_96_1","article-title":"The charactetistics of patients with non-small cell lung cancer with complete response treated with ZD1839.","volume":"22","author":"Wu YL","year":"2003","unstructured":"Wu YL , YangX-N, GuL-J: The charactetistics of patients with non-small cell lung cancer with complete response treated with ZD1839.Proc. Am. Soc. Clin. Oncol.22 [Abstract] 2770 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_97_1","article-title":"ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users.","volume":"22","author":"Wong N-S","year":"2003","unstructured":"Wong N-S , LimST, LimW-T, LeongS-S, TanE-H: ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users.Proc. Am. Soc. Clin. Oncol.22 [Abstract] 2790 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_98_1","article-title":"Bronchioalveolar histology and smoking history predict response to gefitinib.","volume":"22","author":"Shah NT","year":"2003","unstructured":"Shah NT , MillerVA, KrisMGet al.: Bronchioalveolar histology and smoking history predict response to gefitinib.Proc. Am. Soc. Clin. Oncol.22 [Abstract] 2524 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_3_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.158"},{"key":"e_1_3_1_3_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.057"},{"key":"e_1_3_1_3_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2818"},{"key":"e_1_3_1_3_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1245"},{"key":"e_1_3_1_3_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0562"},{"key":"e_1_3_1_3_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0870"},{"key":"e_1_3_1_3_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.5.341"},{"key":"e_1_3_1_3_106_1","first-page":"5090","article-title":"Aquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.","volume":"61","author":"Viloria-Petit A","year":"2001","unstructured":"Viloria-Petit A , CrombetT, JothySet al.: Aquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.Cancer Res.61, 5090\u20135101 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_107_1","first-page":"200","article-title":"Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.","volume":"62","author":"Chakravarti A","year":"2002","unstructured":"Chakravarti A , LoefflerJS, DysonNJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.Cancer Res.62, 200\u2013207 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206388"},{"key":"e_1_3_1_3_109_1","first-page":"4340","article-title":"Resistance to Gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidinil 3\u00b4 kinase\/Akt pathway signaling.","volume":"9","author":"She QB","year":"2003","unstructured":"She QB , SalitS, BassoA, MoasserM: Resistance to Gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidinil 3\u00b4 kinase\/Akt pathway signaling.Clin. Cancer Res.9, 4340\u20134346 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1100-03"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14796694.1.2.221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:08Z","timestamp":1719125048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14796694.1.2.221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1517\/14796694.1.2.221"],"URL":"https:\/\/doi.org\/10.1517\/14796694.1.2.221","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}